Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Norrkoping – page 2

189 clinical trials in Norrkoping, Sweden across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Norrkoping at a glance
189
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

189 trials in Norrkoping

Open in trial search

A Phase 3 Study of Once‑Daily Treprostinil Palmitil Inhalation Powder for Adults with Pulmonary Arterial Hypertension

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil Palmitil
  • Sponsor:Insmed Inc.

Study of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD6234
  • Sponsor:AstraZeneca AB

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Cataract

Recruiting

Study of levofloxacin, ketorolac trometamol, and dexamethasone eye drops for preventing inflammation and infection after cataract surgery in adults

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Ntc S.r.l.

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Treatment Study of Arsenic Trioxide, Tretinoin, and Gemtuzumab Ozogamicin for Children and Adolescents with Acute Promyelocytic Leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years
  • Substances:Arsenic Trioxide
  • Sponsor:Associazione Italiana Ematologia Oncologia Pediatrica

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:AstraZeneca AB

A study to compare the effectiveness of rituximab and a placebo in patients with interstitial lung disease associated with rheumatoid arthritis

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Vastra Gotalandsregionen

Study of the effects of stopping elranatamab and teclistamab treatment in patients with multiple myeloma who have had a significant response to therapy.

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Elranatamab
  • Sponsor:Vastra Gotalandsregionen

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Norrkoping

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials focusing on heart failure prevention and treatment of atrial fibrillation. Studies evaluate new therapeutic combinations and strategies for stroke prevention.

  • Heart Failure Management
  • Stroke Prevention
  • Left Ventricular Thrombosis

Advanced research comparing different anticoagulation treatments and novel therapeutic approaches.

02 Oncology and Immunology

Groundbreaking research in colorectal cancer treatment and innovative approaches to schizophrenia spectrum disorders using immunomodulatory therapies.

  • Cancer Treatment Optimization
  • Immunotherapy Applications
  • Mental Health Interventions

Exploring new therapeutic pathways using established medications in novel applications.

03 Infectious Diseases

Studies addressing antibiotic resistance in urinary tract infections and innovative approaches to tuberculosis treatment optimization.

  • Multidrug-Resistant Infections
  • Treatment Duration Optimization
  • Alternative Antibiotic Strategies

Focus on developing more effective treatment regimens with shorter durations.

04 Surgical and Perioperative Care

Research on fluid therapy during laparoscopic surgery and innovative approaches to prosthetic joint infection prevention.

  • Surgical Fluid Management
  • Infection Prevention
  • Post-operative Care

Advancing surgical outcomes through improved perioperative protocols.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.